{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-gord/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field f7a11079-f97d-4edf-867a-215e23a322fc --><h2>Changes</h2><!-- end field f7a11079-f97d-4edf-867a-215e23a322fc -->","summary":null,"htmlStringContent":"<!-- begin item efdf738f-04ab-4521-92e1-fb8bd05cde14 --><!-- begin field b2c65b24-e2e5-470a-9422-7e4495c81fa1 --><p><strong>February to April 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials since the last revision of this topic. The recommendations on primary care management and referral have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management </em>(2014). The lower age limit has been changed from 16 to 18 years. The content has been amended to include proton pump inhibitor doses for treatment of severe oesophagitis, in line with the updated NICE guidance. The topic has also undergone minor restructuring.</p><!-- end field b2c65b24-e2e5-470a-9422-7e4495c81fa1 --><!-- end item efdf738f-04ab-4521-92e1-fb8bd05cde14 -->","topic":{"id":"83831d3c-e98d-5e82-9fb9-cbd189e834d5","topicId":"8116d56b-de40-4191-af22-5152cc8f533c","topicName":"Dyspepsia - proven GORD","slug":"dyspepsia-proven-gord","lastRevised":"Last revised in April 2017","chapters":[{"id":"2b894900-36e2-56c8-9d00-aea95f9acd57","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"491fd89e-ec21-5541-b37c-3579bd40472f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes"},{"id":"69e41821-9e9f-506e-bf29-9bb662d19fc5","slug":"update","fullItemName":"Update"}]},{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac987149-bd5e-543a-8025-d0a50c72b165","slug":"goals","fullItemName":"Goals"},{"id":"c282f1cd-c0cd-5cc2-b030-047fa174fc2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fac73702-952e-57cf-a136-d52c4400cf78","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8add7bfe-1e06-5768-958d-3c09d529c285","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bb66df20-4142-59d4-913e-cf945ca4dacc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0449fde-d38f-58a1-aee2-098d0ab6ff60","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0a206efc-7aca-58e6-8462-5278f905b372","slug":"definition","fullItemName":"Definition"},{"id":"ce8c37c8-0936-52a2-87a7-0cbf130e1ce3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1423a90-52a5-592c-ba4d-7f5a420ac54a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cac2f410-0ab9-55d6-8bb8-acbe7735bd9c","slug":"complications","fullItemName":"Complications"},{"id":"9047f011-fcc3-521a-a802-30ac67c85c10","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","fullItemName":"Management","slug":"management","subChapters":[{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD"}]},{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"}]},{"id":"dc717df5-19a4-5e7d-8391-be3e281ebdc8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"70508c23-67ec-5f56-b6cd-a9612c7e4e9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"713a3147-c4ed-5200-a0ab-51e195929400","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a10b2f69-154b-5dcc-8599-ae8de77e7eda","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6155a413-aefc-5575-b07c-111ad7697022","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73cf98a-26ab-5f78-b8e4-d24d5a849283","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"94379789-e6c4-55fa-b460-965e551f4ea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"64699d48-46e4-5ff1-97c0-8e280c75065c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"f2adc6e7-6727-5aad-b93e-bf49d0cdc82b","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 5152d5aa-d114-4160-80ae-c7129920dfd2 --><h3>Previous changes</h3><!-- end field 5152d5aa-d114-4160-80ae-c7129920dfd2 -->","summary":null,"htmlStringContent":"<!-- begin item c327cb2f-93b1-4d2e-879b-a2b1076e3c10 --><!-- begin field 398a6443-e04f-4c6e-a4ff-aac19dcd8bb9 --><p><strong>December 2016 </strong>— minor update. Subacute cutaneous lupus erythematosus has been added as a very infrequent adverse effect of proton pump inhibitors, in line with a Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (2015).</p><p><strong>May 2014 </strong>— minor update. Domperidone has been removed as a treatment option following the publication of the European Medicines Agency (EMA) document <em>Restrictions on the use of domperidone-containing medications</em> (2014).</p><p><strong>September 2013 </strong>— minor update. Metoclopramide has been removed as a treatment option following the publication of a European Medicines Agency (EMA) document highlighting the risk of neurological adverse effects (2013).</p><p><strong>November 2012 </strong>— reviewed. A literature search was conducted in October 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No changes to clinical recommendations have been made.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic (2012).</p><p><strong>January 2012 </strong>— minor update. McNeil Products Ltd, in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), has published new safety data regarding the association of domperidone with an increased risk of serious ventricular arrhythmias or sudden cardiac death (2011). This topic has been updated to reflect their advice on dosing, adverse effects, and drug interactions. Issued in February 2012.</p><p><strong>January 2012 </strong>— minor update. Information from the manufacturer's Summary of Product Characteristics (SPCs) about the possible interaction between pantoprazole and warfarin has been added to drug interactions (2011). Information from the British National Formulary (BNF) about the potentially serious interaction between proton pump inhibitors and protease inhibitors (atazanavir and saquinavir) has also been added (2011). Issued in January 2012.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— the topic structure has been revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>July 2009 </strong>— minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued advice on the interaction between clopidogrel and proton pump inhibitors. Healthcare professionals are advised to avoid concomitant use of these drugs unless considered essential (2009). Issued in July 2009.</p><p><strong>March to June 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Clinical Excellence (NICE). Issued in July 2005.</p><p><strong>December 2004 </strong>— reviewed and updated to incorporate the National Institute for Health and Care Excellence (NICE) guideline on <em>Dyspepsia </em>(August 2004). Validated in March 2005 and issued in April 2005.</p><p><strong>March 2004 </strong>— updated with additional information for nurse prescribers. Issued March 2004.</p><p><strong>July 2003 </strong>— updated to incorporate information from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Dyspepsia </em>(March 2003). Validated in September 2003 and issued in October 2003.</p><p><strong>November 2000 </strong>— reviewed and updated to incorporate <em>Guidance on the use of proton pump inhibitors (PPIs) in the treatment of dyspepsia</em> (Technology appraisal guidance 7), issued by the National Institute for Health and Care Excellence (July 2000), and the Department of Health referral guidelines for suspected upper gastrointestinal cancers. Validated in November 2000 and issued in December 2000.</p><p><strong>July 2000 </strong>— updated following the suspension of the cisapride licence and resultant withdrawal of cisapride from marketing in the UK. Issued in July 2000.</p><p><strong>June 1998 </strong>— written.</p><!-- end field 398a6443-e04f-4c6e-a4ff-aac19dcd8bb9 --><!-- end item c327cb2f-93b1-4d2e-879b-a2b1076e3c10 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}